Eliem Therapeutics Financials

ELYM Stock  USD 2.76  0.05  1.85%   
Based on the key indicators related to Eliem Therapeutics' liquidity, profitability, solvency, and operating efficiency, Eliem Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Eliem Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 28th of March 2024, Accounts Payable is likely to grow to about 1.1 M, while Other Current Liabilities is likely to drop about 3.2 M. Key indicators impacting Eliem Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.0030.0034
Fairly Down
Slightly volatile
Current Ratio16.219.84
Significantly Down
Slightly volatile
The financial analysis of Eliem Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Eliem Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Eliem Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Eliem Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Eliem Therapeutics.

Net Income

(41.2 Million)

With this module, you can analyze Eliem financials for your investing period. You should be able to track the changes in Eliem Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Eliem Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eliem Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Eliem Therapeutics' assets may result in an increase in income on the income statement.
Evaluating Eliem Therapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Eliem Therapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Eliem Therapeutics' relative financial performance

Chance Of Distress

Less than 20

 
100  
 
Zero
Low
Eliem Therapeutics has less than 20 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Eliem Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Eliem Therapeutics' odds of distress score SHOULD NOT be confused with the real chance of Eliem Therapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Eliem is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Eliem Therapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Eliem Therapeutics' official financial statements usually reflect Eliem Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eliem Therapeutics. For example, before you start analyzing numbers published by Eliem accountants, it's critical to develop an understanding of what Eliem Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Eliem Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eliem Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eliem Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eliem Therapeutics. Please utilize our Beneish M Score to check the likelihood of Eliem Therapeutics' management manipulating its earnings.

Eliem Therapeutics Company Summary

Eliem Therapeutics competes with Agilent Technologies, and Mediwound. Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. Eliem Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS28658R1068
CUSIP28658R106
LocationWashington; U.S.A
Business Address23515 NE Novelty
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websiteeliemtx.com
Phone877 354 3689
CurrencyUSD - US Dollar
You should never invest in Eliem Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Eliem Stock, because this is throwing your money away. Analyzing the key information contained in Eliem Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Eliem Therapeutics Key Financial Ratios

Generally speaking, Eliem Therapeutics' financial ratios allow both analysts and investors to convert raw data from Eliem Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Eliem Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Eliem Therapeutics reports annually and quarterly.

Eliem Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eliem Therapeutics competition to find correlations between indicators driving Eliem Therapeutics's intrinsic value. More Info.
Eliem Therapeutics is one of the top stocks in z score category among related companies. It is rated # 2 in retained earnings category among related companies . Eliem Therapeutics reported last year Retained Earnings of (108.77 Million). Comparative valuation analysis is a catch-all model that can be used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eliem Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eliem Therapeutics' earnings, one of the primary drivers of an investment's value.

Eliem Therapeutics Systematic Risk

Eliem Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eliem Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Eliem Therapeutics correlated with the market. If Beta is less than 0 Eliem Therapeutics generally moves in the opposite direction as compared to the market. If Eliem Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eliem Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eliem Therapeutics is generally in the same direction as the market. If Beta > 1 Eliem Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

About Eliem Therapeutics Financials

What exactly are Eliem Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Eliem Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Eliem Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Eliem Therapeutics investors may use each financial statement separately, they are all related. The changes in Eliem Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eliem Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Eliem Therapeutics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Eliem Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Eliem has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Eliem Therapeutics' financials are consistent with your investment objective using the following steps:
  • Review Eliem Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Eliem Therapeutics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Eliem Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Eliem Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Eliem Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eliem Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Eliem Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0362

At this time, Eliem Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year.

Eliem Therapeutics March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Eliem Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eliem Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eliem Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Eliem Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eliem Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Eliem Therapeutics is a strong investment it is important to analyze Eliem Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Eliem Therapeutics' future performance. For an informed investment choice regarding Eliem Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
To learn how to invest in Eliem Stock, please use our How to Invest in Eliem Therapeutics guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Eliem Stock analysis

When running Eliem Therapeutics' price analysis, check to measure Eliem Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eliem Therapeutics is operating at the current time. Most of Eliem Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eliem Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eliem Therapeutics' price. Additionally, you may evaluate how the addition of Eliem Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Eliem Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eliem Therapeutics. If investors know Eliem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eliem Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.46)
Return On Assets
(0.14)
Return On Equity
(0.32)
The market value of Eliem Therapeutics is measured differently than its book value, which is the value of Eliem that is recorded on the company's balance sheet. Investors also form their own opinion of Eliem Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eliem Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eliem Therapeutics' market value can be influenced by many factors that don't directly affect Eliem Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eliem Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eliem Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eliem Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.